{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T18:36:10Z","timestamp":1792866970121,"version":"4.5.0"},"reference-count":52,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The stability of intravenous drug admixtures is essential for ensuring safety, efficacy, and efficient resource utilization in clinical practice. This systematic review and meta-analysis evaluated the physicochemical stability of intravenous anticancer and supportive-care admixtures and examined the influence of drug class, storage temperature, light exposure, container type, and diluent selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The review followed PRISMA 2020 guidelines and was registered with PROSPERO (CRD420261368183). Thirty-three studies were included. Random-effects models were used to estimate pooled stability durations, with subgroup analyses, meta-regression, and risk-of-bias assessment across six domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The pooled mean maximum stability duration was 30.7 days (95% CI 20.1\u201341.3; prediction interval 1.4\u201360.0 days), with extreme heterogeneity (I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200999.7%), limiting generalizability. Monoclonal antibodies generally showed longer stability than cytotoxic agents, particularly under refrigeration. Refrigeration was associated with modestly longer stability, while light exposure appeared to reduce stability, although evidence was limited. Container and diluent effects were variable and drug dependent. Only 12.1% of studies included microbiological assessment, and overall study quality was moderate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intravenous drug admixtures may remain physicochemically stable beyond manufacturer-defined beyond-use dates under controlled conditions. However, extended beyond-use dating should not be based on physicochemical evidence alone. Drug-specific assessment, sterility assurance, and preferably local validation are required before implementation in hospital pharmacy practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261498052","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:41:43Z","timestamp":1792640503000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and hospital pharmacy implications of extended beyond-use dating for intravenous anticancer and supportive care admixtures: A systematic review and meta-analysis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9578-3201","authenticated-orcid":false,"given":"Sadaf","family":"Hameed","sequence":"first","affiliation":[{"name":"University of Central Punjab"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Zafar","sequence":"additional","affiliation":[{"name":"University of Central Punjab"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/or.2024.1415677"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85077-w"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5108-654"},{"key":"e_1_3_3_5_2","first-page":"965","article-title":"Patient-, care partner-, and clinician-proposed solutions to address the time toxicity of cancer care","volume":"33","author":"Johnson WV","year":"2025","unstructured":"Johnson WV, Valisekka SS, Ogunleye OO, et al. Patient-, care partner-, and clinician-proposed solutions to address the time toxicity of cancer care. Support Care Cancer 2025; 33: 965.","journal-title":"Support Care Cancer"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264928"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-023-00518-3"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/08971900221134836"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211008527"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2023-003769"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1515\/pthp-2020-0002"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11040458"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-023-01716-7"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2020.05.014"},{"key":"e_1_3_3_15_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J 2021; 372: n71.","journal-title":"Br Med J"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0495-9"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/43.12.3022"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(90)90188-A"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23403"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120035"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214546016"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1515\/pthp-2018-0015"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00336-7"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217731506"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218764285"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218772885"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.5639\/gabij.2020.0904.026"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.04.042"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219868516"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/0018578719888912"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220940410"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114209"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.02.021"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211016079"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002620"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002597"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-002823"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1515\/pthp-2022-0007"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-024-00496-0"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/15593258241293220"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.5639\/gabij.2024.1302.011"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231170583"},{"key":"e_1_3_3_43_2","first-page":"107815522513387","article-title":"Long term and simulated in-use stabilities of irinotecan chemotherapy polyolefin infusion bags in dose banding conditions","volume":"32","author":"Andre C","year":"2025","unstructured":"Andre C, Lethier L, Guillaume YC. Long term and simulated in-use stabilities of irinotecan chemotherapy polyolefin infusion bags in dose banding conditions. J Oncol Pharm Pract 2025; 32: 10781552251338763.","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241279018"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2023-003844"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-02079-8"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy13010022"},{"key":"e_1_3_3_48_2","doi-asserted-by":"crossref","unstructured":"Guillaume Y Andr\u00e9 C Lethier L. Fully validated HPLC-UV detection method associated with colour variation control for evaluation of the stability of 5-fluorouracil chemotherapy polyolefin infusion bags at dose banding. Eur J Hosp Pharm 2026: ejhpharm-2025-004739. https:\/\/doi.org\/10.1136\/ejhpharm-2025-004739","DOI":"10.1136\/ejhpharm-2025-004739"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231152618"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.3109\/08039488.2013.830773"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039471"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-026-03121-0"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2024.020101"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261498052","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261498052","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261498052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T17:50:32Z","timestamp":1792864232000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261498052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":52,"alternative-id":["10.1177\/10781552261498052"],"URL":"https:\/\/doi.org\/10.1177\/10781552261498052","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"article-number":"10781552261498052"}}